.Nature Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of clients with HER2+ enhanced bosom cancer and also energetic or dependable mind metastases showed steady intracranial activity and systemic effectiveness of T-DXd.